Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Frontiers in Pharmacology , 2022
What Should I Expect From Treatment at AgeRejuvenation
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
However, it is worth noting that there is a possibility that some Sucrosomial B12 may enter the bloodstream in its intact form and potentially be released at the hepatocytes, this aspect of its absorption and metabolism requires further investigation
